Familial combined hyperlipidemia workshop

Scott M Grundy, A. Chait, J. D. Brunzell

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

In summary, the occurrence of a pattern of multiple lipoprotein phenotypes within single families has been well documented. Although in some families, this pattern could represent the random occurrence of different forms of hyperlipidemia among different family members, the consensus was that in many families there is a common metabolic defect. There was a consensus amongst participants that this common defect is characterized by an overproduction of lipoproteins containing apo B. This overproduction can be manifested as increased plasma levels of VLDL, IDL, LDL, or apo B alone. While the best therapeutic regime is not known for certain, several possible approaches that can correct the abnormalities in plasma lipoprotein levels are available. Most participants agreed that nicotinic acid is the drug of choice with or without bile acid sequestrants, but difficulty with nicotinic acid by some patients prevents its use. Some participants believed that bile acid sequestrants alone or in combination with fibric acids or mevinolin can have a role in treatment of the specific forms of hyperlipidemia often present in this condition. In the absence of a primary prevention trial for FCHL, it seems likely that the best therapeutic approach will remain uncertain. Nonetheless, at the very least, an attempt to lower the elevated levels of LDL cholesterol and total apo B in FCHL seems justified.

Original languageEnglish (US)
Pages (from-to)203-207
Number of pages5
JournalArteriosclerosis
Volume7
Issue number2
StatePublished - 1987

Fingerprint

Familial Combined Hyperlipidemia
Apolipoproteins B
Lipoproteins
Education
Niacin
Hyperlipidemias
Bile Acids and Salts
Consensus
Fibric Acids
Lovastatin
Primary Prevention
LDL Cholesterol
Therapeutics
Phenotype
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Grundy, S. M., Chait, A., & Brunzell, J. D. (1987). Familial combined hyperlipidemia workshop. Arteriosclerosis, 7(2), 203-207.

Familial combined hyperlipidemia workshop. / Grundy, Scott M; Chait, A.; Brunzell, J. D.

In: Arteriosclerosis, Vol. 7, No. 2, 1987, p. 203-207.

Research output: Contribution to journalArticle

Grundy, SM, Chait, A & Brunzell, JD 1987, 'Familial combined hyperlipidemia workshop', Arteriosclerosis, vol. 7, no. 2, pp. 203-207.
Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis. 1987;7(2):203-207.
Grundy, Scott M ; Chait, A. ; Brunzell, J. D. / Familial combined hyperlipidemia workshop. In: Arteriosclerosis. 1987 ; Vol. 7, No. 2. pp. 203-207.
@article{40ec97d8ed01434bba3b60c72becbf0b,
title = "Familial combined hyperlipidemia workshop",
abstract = "In summary, the occurrence of a pattern of multiple lipoprotein phenotypes within single families has been well documented. Although in some families, this pattern could represent the random occurrence of different forms of hyperlipidemia among different family members, the consensus was that in many families there is a common metabolic defect. There was a consensus amongst participants that this common defect is characterized by an overproduction of lipoproteins containing apo B. This overproduction can be manifested as increased plasma levels of VLDL, IDL, LDL, or apo B alone. While the best therapeutic regime is not known for certain, several possible approaches that can correct the abnormalities in plasma lipoprotein levels are available. Most participants agreed that nicotinic acid is the drug of choice with or without bile acid sequestrants, but difficulty with nicotinic acid by some patients prevents its use. Some participants believed that bile acid sequestrants alone or in combination with fibric acids or mevinolin can have a role in treatment of the specific forms of hyperlipidemia often present in this condition. In the absence of a primary prevention trial for FCHL, it seems likely that the best therapeutic approach will remain uncertain. Nonetheless, at the very least, an attempt to lower the elevated levels of LDL cholesterol and total apo B in FCHL seems justified.",
author = "Grundy, {Scott M} and A. Chait and Brunzell, {J. D.}",
year = "1987",
language = "English (US)",
volume = "7",
pages = "203--207",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Familial combined hyperlipidemia workshop

AU - Grundy, Scott M

AU - Chait, A.

AU - Brunzell, J. D.

PY - 1987

Y1 - 1987

N2 - In summary, the occurrence of a pattern of multiple lipoprotein phenotypes within single families has been well documented. Although in some families, this pattern could represent the random occurrence of different forms of hyperlipidemia among different family members, the consensus was that in many families there is a common metabolic defect. There was a consensus amongst participants that this common defect is characterized by an overproduction of lipoproteins containing apo B. This overproduction can be manifested as increased plasma levels of VLDL, IDL, LDL, or apo B alone. While the best therapeutic regime is not known for certain, several possible approaches that can correct the abnormalities in plasma lipoprotein levels are available. Most participants agreed that nicotinic acid is the drug of choice with or without bile acid sequestrants, but difficulty with nicotinic acid by some patients prevents its use. Some participants believed that bile acid sequestrants alone or in combination with fibric acids or mevinolin can have a role in treatment of the specific forms of hyperlipidemia often present in this condition. In the absence of a primary prevention trial for FCHL, it seems likely that the best therapeutic approach will remain uncertain. Nonetheless, at the very least, an attempt to lower the elevated levels of LDL cholesterol and total apo B in FCHL seems justified.

AB - In summary, the occurrence of a pattern of multiple lipoprotein phenotypes within single families has been well documented. Although in some families, this pattern could represent the random occurrence of different forms of hyperlipidemia among different family members, the consensus was that in many families there is a common metabolic defect. There was a consensus amongst participants that this common defect is characterized by an overproduction of lipoproteins containing apo B. This overproduction can be manifested as increased plasma levels of VLDL, IDL, LDL, or apo B alone. While the best therapeutic regime is not known for certain, several possible approaches that can correct the abnormalities in plasma lipoprotein levels are available. Most participants agreed that nicotinic acid is the drug of choice with or without bile acid sequestrants, but difficulty with nicotinic acid by some patients prevents its use. Some participants believed that bile acid sequestrants alone or in combination with fibric acids or mevinolin can have a role in treatment of the specific forms of hyperlipidemia often present in this condition. In the absence of a primary prevention trial for FCHL, it seems likely that the best therapeutic approach will remain uncertain. Nonetheless, at the very least, an attempt to lower the elevated levels of LDL cholesterol and total apo B in FCHL seems justified.

UR - http://www.scopus.com/inward/record.url?scp=0023237538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023237538&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 203

EP - 207

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 2

ER -